Premenstrual Dysphoric Disorder Workup

1. Wyatt K, Dimmock P, O'Brien PMS. Premenstrual syndrome. Clin Evid. 2000. 4:1121-33.

2. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet. 1989 Apr 8. 1(8641):777. [QxMD MEDLINE Link].

3. Endicott J. History, evolution, and diagnosis of premenstrual dysphoric disorder. J Clin Psychiatry. 2000. 61 Suppl 12:5-8. [QxMD MEDLINE Link].

4. Frank RT. The hormonal causes of premenstrual tension. Arch Neurol Psych. 1931. 26:1053-57.

5. Klock SC. Premenstrual dysphoric disorder. Ryan KJ, ed. Kistner's Gynecology and Women's Health. 7th ed. 520-4.

6. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry. 2000. 61 Suppl 12:17-21. [QxMD MEDLINE Link].

7. Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab. 1985 Dec. 61(6):1179-84. [QxMD MEDLINE Link].

8. Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry. 2000. 61 Suppl 12:9-16. [QxMD MEDLINE Link].

9. Boyle CA, Berkowitz GS, Kelsey JL. Epidemiology of premenstrual symptoms. Am J Public Health. 1987 Mar. 77(3):349-50. [QxMD MEDLINE Link].

10. Grady-Weliky TA. Clinical practice. Premenstrual dysphoric disorder. N Engl J Med. 2003 Jan 30. 348(5):433-8. [QxMD MEDLINE Link].

11. Banerjee N, Roy KK, Takkar D. Premenstrual dysphoric disorder--a study from India. Int J Fertil Womens Med. 2000 Sep-Oct. 45(5):342-4. [QxMD MEDLINE Link].

12. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health. 2010 Dec. 13(6):485-94. [QxMD MEDLINE Link].

13. Issa BA, Yussuf AD, Olatinwo AW, Ighodalo M. Premenstrual dysphoric disorder among medical students of a Nigerian university. Ann Afr Med. 2010 Jul-Sep. 9(3):118-22. [QxMD MEDLINE Link].

14. Stout AL, Grady TA, Steege JF, et al. Premenstrual symptoms in black and white community samples. Am J Psychiatry. 1986 Nov. 143(11):1436-9. [QxMD MEDLINE Link].

15. Woods NF, Most A, Dery GK. Prevalene of perimenstrual symptoms. Am J Public Health. 1982 Nov. 72(11):1257-64. [QxMD MEDLINE Link].

16. Chang AM, Holroyd E, Chau JP. Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women Int. 1995 Nov-Dec. 16(6):551-61. [QxMD MEDLINE Link].

17. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018 Jan. 218 (1):68-74. [QxMD MEDLINE Link].

18. Bhatia SC, Bhatia SK. Depression in women: diagnostic and treatment considerations. Am Fam Physician. 1999 Jul. 60(1):225-34, 239-40. [QxMD MEDLINE Link].

19. Baca-Garcia E, Diaz-Sastre C, Ceverino A, García Resa E, Oquendo MA, Saiz-Ruiz J, et al. Premenstrual symptoms and luteal suicide attempts. Eur Arch Psychiatry Clin Neurosci. 2004 Oct. 254(5):326-9. [QxMD MEDLINE Link].

20. Kim SY, Park HJ, Lee H, Lee H. Acupuncture for premenstrual syndrome: a systematic review and meta-analysis of randomised controlled trials. BJOG. 2011 Jul. 118(8):899-915. [QxMD MEDLINE Link].

21. Jang SH, Kim DI, Choi MS. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. BMC Complement Altern Med. 2014 Jan 10. 14:11. [QxMD MEDLINE Link].

22. Goodale IL, Domar AD, Benson H. Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet Gynecol. 1990 Apr. 75(4):649-55. [QxMD MEDLINE Link].

23. Lam RW, Carter D, Misri S, et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res. 1999 Jun 30. 86(3):185-92. [QxMD MEDLINE Link].

24. Krasnik C, Montori VM, Guyatt GH, Heels-Ansdell D, Busse JW. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. Am J Obstet Gynecol. 2005 Sep. 193(3 Pt 1):658-61. [QxMD MEDLINE Link].

25. Parry BL, Cover H, Mostofi N, et al. Early versus late partial sleep deprivation in patients with premenstrual dysphoric disorder and normal comparison subjects. Am J Psychiatry. 1995 Mar. 152(3):404-12. [QxMD MEDLINE Link].

26. Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res. 1998 Oct. 45(4):307-18. [QxMD MEDLINE Link].

27. Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2009. 78(1):6-15. [QxMD MEDLINE Link].

28. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009 Apr. 12(2):85-96. [QxMD MEDLINE Link].

29. drospirenone and ethinyl estradiol (YAZ®) [package insert]. Wayne, NJ: Bayer Health Care Phamaceuticals. 2007. Available at [Full Text].

30. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrual syndrome. J Clin Psychiatry. 2000. 61 Suppl 12:22-7. [QxMD MEDLINE Link].

31. Andersen AN, Larsen JF, Steenstrup OR, Svendstrup B, Nielsen J. Effect of bromocriptine on the premenstrual syndrome. A double-blind clinical trial. Br J Obstet Gynaecol. 1977 May. 84(5):370-4. [QxMD MEDLINE Link].

32. Kullander S, Svanberg L. Bromocriptine treatment of the premenstrual syndrome. Acta Obstet Gynecol Scand. 1979. 58(4):375-8. [QxMD MEDLINE Link].

33. Graham JJ, Harding PE, Wise PH, Berriman H. Prolactin suppression in the treatment of premenstrual syndrome. Med J Aust. 1978 Nov 4. 2(3 Suppl):18-20. [QxMD MEDLINE Link].

34. Werch A, Kane RE. Treatment of premenstrual tension with metolazone: a double-blind evaluation of a new diuretic. Curr Ther Res Clin Exp. 1976 Jun. 19(6):565-72. [QxMD MEDLINE Link].

35. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry. 1990 Mar. 47(3):270-5. [QxMD MEDLINE Link].

36. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1993 Jun. 50(6):467-73. [QxMD MEDLINE Link].

37. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol. 1999 May. 14 Suppl 2:S27-33. [QxMD MEDLINE Link].

38. The Medical Letter. Which SSRI?. Med Lett Drugs Ther. 2003 Nov 24. 45(1170):93-5. [QxMD MEDLINE Link].

39. Steiner M. Recognition of premenstrual dysphoric disorder and its treatment. Lancet. 2000 Sep 30. 356(9236):1126-7. [QxMD MEDLINE Link].

40. Brown J, O' Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009 Apr 15. CD001396. [QxMD MEDLINE Link].

41. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med. 1995 Jun 8. 332(23):1529-34. [QxMD MEDLINE Link].

42. The Medical Letter. Fluoxetine (Sarafem) for premenstrual dysphoric disorder. Med Lett Drugs Ther. 2001 Jan 22. 43(1096):5-6. [QxMD MEDLINE Link].

43. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24. 278(12):983-8. [QxMD MEDLINE Link].

44. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998 Feb. 59(2):76-80. [QxMD MEDLINE Link].

45. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol. 2005. 193:352-60. [QxMD MEDLINE Link].

46. Steiner M, Ravindran AV, LeMelledo JM, Carter D, Huang JO, Anonychuk AM, et al. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry. 2008 Jun. 69(6):991-8. [QxMD MEDLINE Link].

47. Freeman EW, Rickels K, Sondheimer SJ, et al. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol. 1994 Jun. 14(3):180-6. [QxMD MEDLINE Link].

48. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001 Nov. 98(5 Pt 1):737-44. [QxMD MEDLINE Link].

49. Freeman EW, Sondheimer SJ, Sammel MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005. 66:769-73. [QxMD MEDLINE Link].

50. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008 May. 111(5):1175-82. [QxMD MEDLINE Link].

51. Kayatekin ZE, Sabo AN, Halbreich U. Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study. Arch Womens Ment Health. 2008 Jul. 11(3):207-11. [QxMD MEDLINE Link].

52. Wyatt KM, Dimmock PW, Jones PW, Shaughn O''Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999 May 22. 318(7195):1375-81. [QxMD MEDLINE Link].

53. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998 Aug. 179(2):444-52. [QxMD MEDLINE Link].

54. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol. 1991 Aug. 78(2):177-81. [QxMD MEDLINE Link].

55. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998 Nov. 7(9):1157-65. [QxMD MEDLINE Link].

56. Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome?. Control Clin Trials. 1996 Feb. 17(1):60-8. [QxMD MEDLINE Link].

57. Brauser D. Progesterone, Anxiety Affect Premenstrual Dysphoric Disorder. Available at http://www.medscape.com/viewarticle/812792. Accessed: October 28, 2013.

58. Dell DL. Premenstrual Syndrome, Premenstrual Dysphoric Disorder, and Premenstrual Exacerbation of Another Disorder. Clin Obstet Gynecol. 2004 Sep. 47(3):568-575. [QxMD MEDLINE Link].

59. Gingnell M, Morell A, Bannbers E, Wikström J, Sundström Poromaa I. Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder. Horm Behav. 2012 Sep. 62(4):400-6. [QxMD MEDLINE Link].

60. Management of Premenstrual Syndrome: Green-top Guideline No. 48. BJOG. 2017 Feb. 124 (3):e73-e105. [QxMD MEDLINE Link].

61. Steinberg EM, Cardoso GM, Martinez PE, Rubinow DR, Schmidt PJ. Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depress Anxiety. 2012 Jun. 29 (6):531-40. [QxMD MEDLINE Link].

62. Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Oct. 72 (10):1037-44. [QxMD MEDLINE Link].

63. Ozgoli G, Selselei EA, Mojab F, Majd HA. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med. 2009 Aug. 15 (8):845-51. [QxMD MEDLINE Link].

64. Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017 Aug. 217 (2):150-166. [QxMD MEDLINE Link].

65. Canning S, Waterman M, Orsi N, Ayres J, Simpson N, Dye L. The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010 Mar. 24 (3):207-25. [QxMD MEDLINE Link].

66. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod. 2004 Sep. 19 (9):2152-5. [QxMD MEDLINE Link].

67. Ismaili E, Walsh S, O'Brien PMS, Bäckström T, Brown C, Dennerstein L, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016 Dec. 19 (6):953-958. [QxMD MEDLINE Link].

Thwe T Htay, MD, FACP Associate Professor of Medicine, Medical Skills Course Director, Department of Medical Education, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Thwe T Htay, MD, FACP is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Amy HoangAnh Doan, MD Resident Physician, Department of Pediatrics, University of Texas Health Science Center at Houston, McGovern Medical School

Amy HoangAnh Doan, MD is a member of the following medical societies: American Medical Association, National Med-Peds Residents' Association, Texas Medical Association

Disclosure: Nothing to disclose.

KoKo Aung, MD, MPH, FACP Professor of Internal Medicine and Associate Academic Dean, Vice President, Texas Tech University Health Sciences Center at El Paso, Paul L Foster School of Medicine

KoKo Aung, MD, MPH, FACP is a member of the following medical societies: American College of Physicians, Society of General Internal Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ana Hategan, MD, FRCPC Associate Clinical Professor, Department of Psychiatry and Behavioral Neurosciences, Division of Geriatric Psychiatry, McMaster University School of Medicine; Geriatric Psychiatrist, St Joseph's Health Care Hamilton, Canada

Ana Hategan, MD, FRCPC is a member of the following medical societies: Canadian Academy of Geriatric Psychiatry, Canadian Coalition for Seniors' Mental Health, Canadian Psychiatric Association, International Psychogeriatric Association, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Book royalties and/or honoraria for articles from American Psychiatric Publishing, Springer, and Current Psychiatry.

Ronald C Albucher, MD Chief Medical Officer, Westside Community Services; Consulting Staff, California Pacific Medical Center

Ronald C Albucher, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: Nothing to disclose.

John Carrick, MD Consulting Staff, Department of Psychiatry, Flagstaff Medical Center

John Carrick, MD is a member of the following medical societies: American Association for Geriatric Psychiatry

Disclosure: Nothing to disclose.

Romeo Papica II MD Staff Physician, Premier Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article